A 300 ns (300,000 Ps) molecular dynamics simulation revealed that both huPrP and moPrP structures reached a stable state at ~200 ns and continues till the end of the simulation (Determine 4(a)). displayed conspicuous structural differences between huPrP and moPrP. We identified 10 huPrP and 6 moPrP linear B-cell epitopes from the prion protein 3D structure where 5 out of 10 Prp2 huPrP and 3 out of 6 moPrP B-cell epitopes were predicted to be potentially toxic in immunoinformatics approaches. Herein, we demonstrate that some of the predicted potentially toxic epitopes identified by thein silicoanalysis were similar to the epitopes recognized by the toxic antibodies such as ICSM18 (146159), POM1 (138147), D18 (133157), ICSM35 (91110), D13 (95103) and POM3 (95100). Thisin CCT007093 CCT007093 silicostudy reveals the role of host specificity of PrPCin epitope-specific anti-PrP antibody toxicity. KEYWORDS:Cellular prion protein (PrPc), molecular dynamics simulation, immunoinformatics, B-cell epitope, neurotoxicity == 1. Introduction == Prion diseases are believed to be caused by the pathogenic conversion of the cellular prion protein (PrPC) to an abnormal and partially protease resistant PrPSc[1,2]. ThePrnpgene encodes the prion protein and this gene is located on chromosome 2 in mice and on chromosome 20 in human [3,4]. Structurally, usually PrPCis divided in a structured C-terminal domain name (made up of GPI anchor attachment site) and an internally disordered N-terminal domain name, two N-linked glycosylation sites, and a single disulphide bridge [5,6]. The N-terminal end of the mature PrP protein contains a positively charged motif involved in endocytic trafficking [79]. In addition, in the N-terminal domain name there is a series of four octapeptide repeats, each of which contains a histidine residue that helps coordinate the binding of divalent metal ions [10,11]. Human PrPCis made up of 253-amino acid residues that is trimmed down to 209-amino-acids after the C- and N-terminal signal peptides are removed [12,13]. On the other hand, prior to post-translational changes, the mouse PrPCis a 254 amino acid protein that matures to a 208 amino acid residues [14]. The full-length human PrP (huPrP) and mouse PrP (moPrP) are divided into three major parts, including the flexible tail (FT) region (23123), the octapeptide repeat (OR) region (5090) located within the FT region and the globular domain name (GD) region (124230). Antibody-mediated therapy is considered the most promising treatment strategy for prion diseases [1525]. Several anti-PrP antibodies have shown potential for the treatment of prion diseases, including 6H4 [26], ICSM18, ICSM35 [27], POM1, POM2, POM3 [28], D13, D18 [29,30] and SAF32, SAF70 [31,32]. However, some of these antibodies caused hippocampal toxicity [33,34]. Some of the anti-PrP antibodies such as ICSM35, D13 (FT region) [3336] and ICSM18, D18 (GD region) [3335] that shared comparable epitope sequences showed contradictory results in several studies. A study by Solforosi and co-workers showed that anti-PrP D13 antibody (epitope 95105) caused widespread neuronal loss in the hippocampal region following stereotaxic injection [34]. Further, Reimannet al. confirmed that D13 antibody induced fast, dose-dependent, on-target (hippocampus) neurotoxicity [33]. Stereotaxic injection of ICSM18 (epitope 143153) in the hippocampal region of C57BL/10 mice did not show intensive neuronal apoptosis [35]. On the other hand, a comprehensive follow-up research by Reimannet al. exposed that intracerebral ICSM18 antibody shot to C57BL/10 mice induced fast, dose-dependent, on-target neurotoxicity [33]. Furthermore, other research using POM1 monoclonal antibody that stocks an identical epitope with ICSM18 in addition has led to serious neurotoxicity [3638]. Administration of the octa-repeat (OR)-particular antibody, 4H11 antibody, resulted in behavioural deficits and extensive neuronal astrogliosis and loss in mice [39]. Nevertheless, POM2 antibody, which also binds an epitope for the OR area did not display any toxicity [33,36]. Of take note, a humanized edition of ICSM18, referred to as PRN100, didn’t trigger apoptosis in the hippocampus of C57BL/10 mice [35]. Actually, Klyubinet al. demonstrated that peripheral administration of PRN100 blocks severe A synaptotoxicity [40]. Apart from the sponsor specificity of PrPC(human being vs mouse), it’s important to also take note the variations in the sort of the immunogens utilized to create the anti-PrP antibodies (full-length vs truncated; recombinant vs indigenous). For example, D13 and D18 antibodies had been panned against dispersed Syrian hamster PrP (SHaPrP 2730) by immunizing thePrnp0/0msnow [29], while ICSM18 and ICSM35 antibodies had been made by immunizingPrnp0/0msnow using human being truncated recombinant PrP 91-231 or PrP 91-231 conformations respectively [27]. Recombinant PrP 91-231 can be a soluble -helical monomer that’s vunerable to proteinase K, whereas PrP 91-231 can be a soluble monomer with CCT007093 a higher -sheet content material and partly resistant to treatment with proteinase K [41]. Furthermore, POM antibodies had been made by immunizing thePrnp0/0msnow using mouse full-length recombinant PrP.